Looking back at 10 years of trastuzumab therapy: What is the role of HER2 testing? A systematic review of health economic analyses

Personalized Medicine

Volumn 6, Issue 2, 2009, Pages 193-215

  Ferrusi, Ilia L ^a   Marshall, Deborah A ^b   Kulin, Nathalie A ^c   Leighl, Natasha B ^d   Phillips, Kathryn A ^e  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cost effectiveness; Cost utility; HER2; Herceptin; Sensitivity; Specificity; Targeted therapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; BREAST METASTASIS; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; EARLY CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH ECONOMICS; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 67651166973     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.6.2.193     Document Type: Review

References (45)

1. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al.: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
2. McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209-243 (2002).
3. De Laurentiis M, Cancello G, Zinno L et al.: Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann. Oncol. 16(Suppl. 4), IV7-IV13 (2005).
4. Dendukuri N, Khetani K, McIsaac M, Brophy J: Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. Can. Med. Assoc. J. 176, 1429-1434 (2007).
5. Wolff AC, Hammond ME, Schwartz JN et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145 (2007).
6. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6), 620-630 (2008).
7. Minhas R: How much will herceptin really cost? The money is already there. BMJ 333(7580), 1219-1220 (2006).
8. Dillon A, Littlejohns P: How much will herceptin really cost? Balancing local and national priorities is not new. BMJ 333(7580), 1219-1220 (2006).
9. Kondro W, Sibbald B: Patient demand and politics push Herceptin forward. Can. Med. Assoc. J. 173(4), 347-348 (2005).
10. Metcalfe S, Evans J: PHARMAC responds on Herceptin assumptions and decisions. N. Z. Med. J. 120(1260), U2692 (2007).
11. Metcalfe S, Evans J, Priest G: PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N. Z. Med. J. 120(1256), U2593 (2007).
12. Rosevear M: PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception? N. Z. Med. J. 119(1235), U2014 (2006).
13. Petersen S: Roche responds to the 'Herceptin or deception' article. N. Z. Med. J. 119(1237), U2069 (2006).
14. Breast Cancer Advocacy Coalition; Burgess EP: Breast Cancer Advocacy Coalition responds to the 'Herceptin or deception' article. N. Z. Med. J. 119(1237), U2065 (2006).
15. Hillner BE, Smith TJ: Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J. Clin. Oncol. 25, 611-613 (2007).
16. Drummond MF, Sculpher MJ, Torrance GW, O'Brian BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford, UK (2005).
17. Perik PJ, de Korte MA, van Veldhuisen DJ, Gietema JA, Sleijfer DT, de Vries EGE: Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev. Anticancer Ther. 7(12), 1763-1771 (2007).
18. Fleiss JL: The statistical basis of meta-analysis. Stat. Methods Med. Res. 2, 121-145 (1993).
19. Vernaglia PR, Cunha FM, Correa M et al.: Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil. Breast Cancer Res. Treat. 106(Suppl. 1) S106 (2007) (Abstract).
20. + breast cancer trials. San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA, 8-11 December (2005).
21. Hornberger J, Kerrigan M, Foutel V Cost-effectiveness of trastuzmab (Herceptin®) for treatment of metastatic breast cancer. Ann. Oncol. 13, 52 (2002)
22. Ragaz J, Spinelli JJ: [2029] Cost-benefit estimates of adjuvant (Adj) trastuzumab (herceptin, H) for early breast cancer (BrCa). San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA, 8-11 December (2005).
23. Millar JA, Millward MJ: Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model. Pharmaroeconomics 25, 429-442 (2007).
24. Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramackers D: Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 87(2), 146-159 (2008).
25. Elkin EB, Weinstein MC, Winer EP, Kuntz KM, Schnitt SJ, Weeks JC: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 22, 854-863 (2004).
26. Norum J, Risberg T, Olsen JA: A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann. Oncol. 16, 909-914 (2005).
27. Poncet B, Bachelor T, Colin C et al.: Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis. Am. J Clin. Oncol. 31(4), 363-368 (2008).
28. National Institute for Clinical Excellence: Guidance on the use of trastuzumab for the treatment of advanced breast cancer. 34, 1-14 (2002).
29. Slamon DJ, Leyland-Jones BSS, Fuchs H et al.: Use ofchemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
30. Dedes KJ, Szucs TD, Imesch P, Fedier A, Fehr MK, Fink D: Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann. Oncol. 18, 1493-1499 (2007).
31. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J: Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann. Oncol. 19, 487-495 (2008).
32. Garrison LP, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA: Cost-effectiveness analysis of trastuzurnab it. the adjuvant setting for treatment of HER2-positive breast cancer. Cancer 110(3), 489-498 (2007).
33. Kurian AW, Thompson RN, Gaw AF, Arai S, Ortiz R, Garber AM: A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J. Clin. Oncol. 25, 634-641 (2007).
34. Liberato NL, Marchetti M, Barosi G: Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 25, 625-633 (2007).
35. National Institute for Health and Clinical Excellence: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer. 107 (2006).
36. Morelle M, Haslé E, Treilleux I, Michot JP, Bachelot T: Cost-effectiveness analysis of strategies for HER2 testing of breast cancer patients in France. Int. J. Technol Assess. Health Care 22, 396-401 (2006).
37. Dranitsaris G, Norris B, Hanna W, O'Malley F, Gelmon K: Identifying the optimal testing of HER2 testing in patients with breast cancer: a Canadian economic evaluation. Curr. Oncol. 10, 36-44 (2003).
38. Alvarez R, Albarracin C, Valero V, Sabin A, Johnson M, Hortobagyi G: Discordance rates of HER-2 expression between breast primary tumors and paired metastatic tumor specimens. 2008 American Society of Clinical Oncology Breast Cancer Symposium (2008) (Abstract 121).
39. Simmons C, Miller N, Geddie W, Gianfelice D, Dranitsaris G, Oldfield M, Clemons M: Changes in breast tumor receptor status with time: a prospective study assessing the impact of obtaining confirmatory biopsy at metastatic recurrence on patient management. 2008 American Society of Clinical Oncology Breast Cancer Symposium (2008) (Abstract 124).
40. McKeage K, Lyseng-Williamson KA: Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 6(8), 699-719 (2008).
41. Younis T, Skedgel C: Is trastuzumab a cost-effective treatment for breast cancer? Expert Rev. Pharmacaeconomics Outcomes Res. 8(5), 433-442 (2008).
42. Hofmann M, Stoss O, Gaiser T et al.: Central HER2 IHC and FISH analysis-in a trastuzumab (Herceptin) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J. Clin. Pathol. 61(1), 89-94 (2008).
43. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672 (2005).
44. Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Kiichiro T: The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res. Treat. 109, 559-566 (2008).
45. Norum J, Olsen JA, Wist EA, Lonnin PE: Trastuzumab in adjuvant breast cancer therapy: a model based cost-effectiveness analysis. Acta Oncol. 46, 153-164 (2007).